Stockscreener 앱 받기
0.5754
8.43%
-0.053
시장 영업 전:
.58
0.0046
+0.80%
Invivyd Inc 주식(IVVD)의 최신 뉴스
Invivyd Inc (NASDAQ: IVVD): Should Value Hunters Buy It? - Stocksregister
Invivyd Inc (IVVD) expanding its growth trajectory ahead - Sete News
Guggenheim Upgrades Invivyd Inc (IVVD) to a Buy from a Neutral - knoxdaily.com
Market Recap Check: Invivyd Inc (IVVD)’s Negative Finish at 0.64, Up/Down -3.97 - DWinneX
Will Invivyd Inc (IVVD) meet earnings estimates this quarter? - uspostnews.com
What is Invivyd Inc (IVVD) Stock Return on Shareholders’ Capital? - Sete News
Guggenheim upgrades Invivyd Inc (IVVD) rating to a Buy - knoxdaily.com
Danaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal terms - Endpoints News
IVVD Stock Price and Chart — NASDAQ:IVVD - TradingView
Invivyd (IVVD) Secures $30M Loan Facility from Silicon Valley Ba - GuruFocus
Invivyd Inc (IVVD) Stock: A Comprehensive 52-Week Review - investchronicle.com
Invivyd secures $30 million loan for COVID-19 antibody development By Investing.com - Investing.com South Africa
What's Going On With Invivyd Stock On Monday? - AOL.com
Can you now get a good deal on Invivyd Inc’s shares? - uspostnews.com
Invivyd Announces $30 Million Loan Facility With Silicon Valley Bank - citybiz
Invivyd (IVVD) Secures $30 Million Loan Facility from Silicon Valley Bank - GuruFocus
Invivyd gets $30M term loan facility from Silicon Valley Bank - MSN
Invivyd Secures $30 Million Loan from SVB - TipRanks
Invivyd (IVVD) Secures $30M Loan Facility from Silicon Valley Bank | FCNCA Stock News - GuruFocus
Invivyd Enters $30 Mln Term Loan Facility With Silicon Valley Bank - Nasdaq
Invivyd secures $30 million loan for COVID-19 antibody development - Investing.com
Invivyd, Inc. Secures $30 Million Term Loan Facility from Silicon Valley Bank to Advance Viral Infectious Disease Pipeline - Nasdaq
Invivyd Lands Strategic $30M Financing Deal: What This Means for VYD2311's FDA Journey - Stock Titan
Invivyd (IVVD) Secures $30 Million Loan Facility from Silicon Va - GuruFocus
Invivyd - WACH
Multiple insider buying at Advantage Energy (AAV) - The Globe and Mail
Invivyd Inc (NASDAQ: IVVD) – Analysts’ Views Revised To A Positive - stocksregister.com
A stock that deserves closer examination: Invivyd Inc (IVVD) - uspostnews.com
Invivyd, Inc. (NASDAQ:IVVD) Sees Large Drop in Short Interest - MarketBeat
Invivyd Appoints Ajay Royan to its Board of Directors - citybiz
Invivyd adds venture capitalist Ajay Royan to board By Investing.com - Investing.com South Africa
Invivyd Appoints Ajay Royan to Board of Directors - TipRanks
Invivyd adds venture capitalist Ajay Royan to board - Investing.com India
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors - The Manila Times
Invivyd’s (IVVD) Buy Rating Reiterated at D. Boral Capital - Defense World
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates - MSN
INVIVYD SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI - Business Wire
Invivyd Reports Strong Revenue Growth and Promising Developments - TipRanks
Invivyd earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Invivyd, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 -March 20, 2025 at 08:12 am EDT - MarketScreener
Invivyd, Inc. SEC 10-K Report - TradingView
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Invivyd, Inc. Reports 48% Q4 Revenue Growth for PEMGARDA™ and Advances Next-Generation Antibody VYD2311 - Nasdaq
Invivyd, Inc. Full Year Loss Decreases, But Misses Estimates - Nasdaq
Invivyd (IVVD) Projected to Post Earnings on Thursday - Defense World
Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now? - Yahoo Finance
D. Boral Capital Reiterates Buy Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
Invivyd reports pemivibart maintains efficacy against SARS-CoV-2 By Investing.com - Investing.com Canada
Invivyd reports pemivibart maintains efficacy against SARS-CoV-2 - Investing.com India
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 - The Manila Times
Invivyd's COVID Treatment Still Works Against Elusive LP.8.1 VariantCritical News for Immunocompromised Patients - StockTitan
Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody - Simply Wall St
Invivyd Inc [IVVD] Insider Activity: An Update for Investors - Knox Daily
Invivyd Inc’s Banking’s 100-Day Moving Average at 0.8392: Will the Stock Break Through? - investchronicle.com
Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025 - Insider Monkey
0.39%
3.66%
자본화:
|
볼륨(24시간):